Silvercrest Asset Management Group LLC Has $6.19 Million Stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Silvercrest Asset Management Group LLC lowered its stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 1.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 166,814 shares of the company’s stock after selling 1,658 shares during the quarter. Silvercrest Asset Management Group LLC’s holdings in Amphastar Pharmaceuticals were worth $6,194,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Pacer Advisors Inc. increased its position in Amphastar Pharmaceuticals by 51,977.4% during the 4th quarter. Pacer Advisors Inc. now owns 1,350,368 shares of the company’s stock worth $50,139,000 after purchasing an additional 1,347,775 shares in the last quarter. D.A. Davidson & CO. bought a new stake in shares of Amphastar Pharmaceuticals during the fourth quarter worth $417,000. Barclays PLC increased its holdings in shares of Amphastar Pharmaceuticals by 53.3% during the third quarter. Barclays PLC now owns 74,456 shares of the company’s stock worth $3,613,000 after buying an additional 25,878 shares in the last quarter. Polaris Capital Management LLC bought a new position in shares of Amphastar Pharmaceuticals in the 4th quarter valued at $910,000. Finally, Raymond James Financial Inc. bought a new position in shares of Amphastar Pharmaceuticals in the 4th quarter valued at $3,450,000. 65.09% of the stock is currently owned by institutional investors and hedge funds.

Amphastar Pharmaceuticals Trading Up 2.2%

NASDAQ AMPH opened at $24.86 on Monday. The firm has a market capitalization of $1.18 billion, a PE ratio of 8.29, a price-to-earnings-growth ratio of 2.19 and a beta of 0.78. The business’s 50-day moving average price is $25.43 and its two-hundred day moving average price is $33.72. The company has a current ratio of 3.43, a quick ratio of 2.61 and a debt-to-equity ratio of 0.82. Amphastar Pharmaceuticals, Inc. has a 12 month low of $22.64 and a 12 month high of $53.96.

Insider Buying and Selling

In other Amphastar Pharmaceuticals news, CFO William J. Peters sold 4,231 shares of the stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $27.54, for a total transaction of $116,521.74. Following the completion of the sale, the chief financial officer now owns 97,363 shares of the company’s stock, valued at approximately $2,681,377.02. This represents a 4.16% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders have sold a total of 5,231 shares of company stock valued at $142,752 over the last ninety days. 27.50% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on AMPH shares. Wells Fargo & Company reduced their price objective on Amphastar Pharmaceuticals from $40.00 to $35.00 and set an “overweight” rating on the stock in a research report on Thursday, May 8th. Piper Sandler lowered their price objective on Amphastar Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating for the company in a research note on Friday, March 21st. Needham & Company LLC reiterated a “hold” rating on shares of Amphastar Pharmaceuticals in a report on Thursday, April 10th. Finally, JPMorgan Chase & Co. reissued a “neutral” rating and set a $30.00 target price (down from $45.00) on shares of Amphastar Pharmaceuticals in a report on Monday, May 12th. Four investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $32.33.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.